-transparent.png){kind=logo}
The clinical significance of neuron-specific enolase (NSE) as a tumour marker was evaluated in 54 patients with seminoma. Before orchiectomy NSE was elevated in six out of 21 patients with stage I seminoma and 11 out of 16 patients with metastases. After orchiectomy NSE normalised in all evaluated stage I cases, but was still elevated in six out of 12 patients with metastatic disease. NSE monitored the effect of cisplatin-based chemotherapy in patients with metastases. In some patients, increased serum NSE was found together with raised levels of human choriogonadotropin (HCG) and lactate dehydrogenase (LDH), while in others only NSE was elevated. No false positive NSE values were observed. NSE seems to be a clinically worthwhile serum tumour marker for monitoring seminoma patients, with a sensitivity and specificity of the same order as HCG.
S D Fosså, and
O Klepp, and
E Paus
September 1987,
Cancer,
S D Fosså, and
O Klepp, and
E Paus
January 1996,
International urology and nephrology,
S D Fosså, and
O Klepp, and
E Paus
November 1989,
Journal of the National Cancer Institute,
S D Fosså, and
O Klepp, and
E Paus
January 1985,
Gan to kagaku ryoho. Cancer & chemotherapy,
S D Fosså, and
O Klepp, and
E Paus
October 1993,
Lancet (London, England),
S D Fosså, and
O Klepp, and
E Paus
January 1993,
European urology,
S D Fosså, and
O Klepp, and
E Paus
August 1983,
Zeitschrift fur Kinderchirurgie : organ der Deutschen, der Schweizerischen und der Osterreichischen Gesellschaft fur Kinderchirurgie = Surgery in infancy and childhood,
S D Fosså, and
O Klepp, and
E Paus
September 1996,
European journal of cancer (Oxford, England : 1990),
S D Fosså, and
O Klepp, and
E Paus
December 1994,
Harefuah,
S D Fosså, and
O Klepp, and
E Paus
January 1993,
European urology,
